

continue to assess market-based fees, whenever practical and feasible.

(9) 40 U.S.C. § 1314. As discussed in greater detail in Section 4.b(1)(D), above, this easement authority may be used to site antennas and related equipment on Federal property under GSA's jurisdiction, custody or control. The grant may be made without consideration, or with monetary or other consideration, at the discretion of the head of the agency.

(10) Section 412 of the GSA General Provisions, Consolidated Appropriations Act, 2005, Pub. L. 108-447 (Dec. 8, 2004). This provision granted GSA new and additional real property disposition authority and the authority to retain proceeds from the disposal of its real property. In addition to giving GSA authority to retain the net proceeds from its real property disposals, Section 412 granted GSA additional new authority to dispose of its real and related personal property by various means, including by sale, lease, exchange, or otherwise. This authority is in addition to GSA's numerous other existing statutory authorities applicable to the use and disposal of real property under its jurisdiction, custody or control. For GSA-controlled property leased under Section 412 to accommodate antennas and related equipment, the proceeds of any such lease would be deposited into GSA's Federal Buildings Fund.

(11) Subchapters III and IV of Chapter 5 of Subtitle I of Title 40 of the United States Code. These are GSA's traditional authorities for the disposal of surplus property. Surplus real property may be leased under these authorities to site antennas and related equipment on property under the jurisdiction, custody or control of GSA. In light of the Section 412 authority discussed in the immediately preceding paragraph, GSA may now retain the proceeds from such disposals and deposit them into the Federal Buildings Fund.

(12) Federal Management Regulation, 41 C.F.R. §§ 102-79.70 - 79.100. As discussed in Section 4.b(1)(E), above, these sections provide regulatory guidance on siting antennas on Federal property under the jurisdiction, custody or control of GSA.

(13) Office of Management and Budget Circular A-25. As discussed in Section 4.b(1)(G), above, this OMB Circular provides guidelines that GSA should use to assess fees for services it offers and for the sale or use of property or resources under its jurisdiction, custody or control.

## 5. Additional Information

Further information regarding this bulletin may be obtained by contacting Mr. Stanley C. Langfeld, Director, Regulations Management Division, Office of Governmentwide Policy, General Services Administration, at (202) 501-1737, or [stanley.langfeld@gsa.gov](mailto:stanley.langfeld@gsa.gov).

[FR Doc. E7-17755 Filed 9-7-07; 8:45 am]

BILLING CODE 6820-EP-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Rulemaking Making Notice of Approval

On September 5, 2007, the Department of Health and Human Services published a final rule governing error rate reporting under the Child Care and Development Fund (CCDF). In accordance with the Paperwork Reduction Act (PRA), the Office of Management and Budget (OMB) has approved the forms and instructions that will be used to implement the final rule on CCDF error rate reporting. This notice is published under authority of Reporting and Recordkeeping Requirements: Final Rule (1320.11(k)) published August 29, 1995.

Dated: September 4, 2007.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 07-4410 Filed 9-7-07; 8:45 am]

BILLING CODE 4184-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, NCI Community Networks Program.

*Date:* October 4-5, 2007.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard Gaithersburg Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878.

*Contact Person:* Bratin K. Saha, PhD, Scientific Review Administrator, Program Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8041, Bethesda, MD 20892, (301) 402-0371, [sahab@mail.nih.gov](mailto:sahab@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, CA 077-033, 034, 039, 040, "Innovative Technologies for Molecular Analysis of Cancer."

*Date:* October 16, 2007.

*Time:* 8 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Jeffrey E. DeClue, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8059, Bethesda, MD 20892-8329, 301-496-7904, [decluej@mail.nih.gov](mailto:decluej@mail.nih.gov).

*Name of Committee:* National Cancer Institute Initial Review Group, Subcommittee H—Clinical Groups, Subcommittee H—Children's Oncology Group.

*Date:* October 22-23, 2007.

*Time:* 7 p.m. to 9 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Georgetown, 2100 Wisconsin Ave, Washington DC.

*Contact Person:* Timothy C. Meeker, MD, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8103, Bethesda, MD 20892, (301) 594-1279, [meekert@mail.nih.gov](mailto:meekert@mail.nih.gov).

*Name of Committee:* National Cancer Institute Initial Review Group, Subcommittee F—Manpower & Training.

*Date:* October 25, 2007.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Crowne Plaza—Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

*Contact Person:* Lynn M. Amende, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8105, Bethesda, MD 20892, 301-451-4759, [amendel@mail.nih.gov](mailto:amendel@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Application of Emerging Technologies for Cancer Research.

*Date:* October 31–November 1, 2007.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Marvin L. Salin, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7073, Bethesda, MD 20892-8329, 301-496-0694, [msalin@mail.nih.gov](mailto:msalin@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, NCI Small Grant Program.

*Date:* November 6-7, 2007.

*Time:* 8 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications and/or proposals.

*Place:* Renaissance M Street Hotel, 1143 New Hampshire Avenue, NW., Washington, DC 20037.

*Contact Person:* Irina V. Gordienko, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7073, Bethesda, MD 20892-8329, 301-594-1566, [gordienkoiv@mail.nih.gov](mailto:gordienkoiv@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Small Grants Program for Cancer Epidemiology.

*Date:* November 29-30, 2007.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Marriott Bethesda North Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

*Contact Person:* Joyce C. Pegues, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, NIH National Cancer Institute, 6116 Executive Boulevard, Room 7149, Bethesda, MD 20892-8329, 301-594-1286, [peguesj@mail.nih.gov](mailto:peguesj@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

*Dated:* August 30, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-4381 Filed 9-1-07; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice

is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate proposals for support through the RAID program by making available to the research community, on a competitive basis, NCI new agent development contract resources for the preclinical development of drugs and biologics. The outcome of the evaluation will be a decision whether NCI should support the request and make available contract resources for support through the RAID program to the research community and NCI new agent development for the preclinical development of drugs and biologics. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Rapid Access to Intervention Development.

*Date:* October 9-10, 2007.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To evaluate the Rapid Access to Intervention Development Portfolio.

*Place:* Bethesda Marriott, Pooks Hill, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Phyllis G. Bryant, Executive Secretary, Program Analyst, Developmental Therapeutics Program, National Cancer Institute, NIH, 6130 Executive Boulevard, Rm. 8022, Bethesda, MD 20892, (301) 496-8720.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394 Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

*Dated:* August 30, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-4382 Filed 9-7-07; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, CA 07-506: "A Data Resource for Analyzing Blood & Marrow Transplants (U24)".

*Date:* October 1, 2007.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6116 Executive Boulevard, Room 8109, Rockville, MD 20852, (Telephone Conference Call).

*Contact Person:* Sonya Roberson, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8109, Bethesda, MD 20892, 301-594-1182, [robersos@mail.nih.gov](mailto:robersos@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Cellular Oncology (SEP).

*Date:* October 2-3, 2007.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott, Pooks Hill, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Shakeel Ahmad, PhD, Scientific Review Administrator, Research Programs Review Branch, National Cancer Institute, Division of Extramural Activities, 6116 Executive Boulevard, Room 8137, Bethesda, MD 20892-8328, (301) 594-0114, [ahmads@mail.nih.gov](mailto:ahmads@mail.nih.gov).

*Name of Committee:* National Cancer Institute Initial Review Group, Subcommittee I—Career Development.

*Date:* October 25, 2007.

*Time:* 9 a.m. to 8 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Crowne Plaza Washington Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

*Contact Person:* Robert Bird, PhD, Scientific Review Administrator, Resources and Training Review Branch, National